Risk of Myocardial Infarction, Stroke, or Death in New Users of Intravitreal Aflibercept Versus Ranibizumab: A Nationwide Cohort Study

INTRODUCTION: The risk of thromboembolic events or death in patients treated with intravitreal anti-vascular endothelial growth factor (IVT anti-VEGF) is poorly described on a large scale and by molecule. This study aimed to assess the risk of myocardial infarction (MI), stroke, or death in new user...

Descripción completa

Detalles Bibliográficos
Autores principales: Billioti de Gage, Sophie, Bertrand, Marion, Grimaldi, Sébastien, Zureik, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927514/
https://www.ncbi.nlm.nih.gov/pubmed/35072917
http://dx.doi.org/10.1007/s40123-021-00451-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927514/
https://www.ncbi.nlm.nih.gov/pubmed/35072917
http://dx.doi.org/10.1007/s40123-021-00451-1

Ejemplares similares